Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00820950 · ClinicalTrials.gov registry record · Phase 2
A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00820950: Completed Phase 2 study, sponsored by Incyte Corporation.
NCT00820950 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 29 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00820950, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The study is comprised of two parts. The first portion of this study will be a double-blind, Sponsor-unblinded, vehicle-controlled study with application of ruxolitinib or vehicle to paired lesions at least 15 cm apart in patients with active but stable plaque psoriasis. Part 2 of the study is a double-blind, sponsor unblinded, comparison of ruxolitinib with two FDA approved products in patients with active but stable plaque psoriasis.
Primary Outcome
The investigator assessed the severity of the clinical signs erythema, scaling, and thickness for each test site by using a 5-point scale from 0 (no evidence) to 4.0 (severe).
Interventions
- DRUG Placebo cream
- DRUG Ruxolitinib phosphate cream
- DRUG Dovonex® calcipotriene 0.005%
- DRUG Diprolene® AF betamethasone dipropionate 0.05% cream.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2007-05-31 |
| Est. Completion | 2009-04-30 |
| Phase | Phase 2 |
What the finished NCT00820950 record still lists
NCT00820950 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo cream is the first listed.
NCT00820950 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00820950 about?
NCT00820950 is a clinical study titled "A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis". The study is comprised of two parts. The first portion of this study will be a double-blind, Sponsor-unblinded, vehicle-controlled study with application of ruxolitinib or vehicle to paired lesions at least 15 cm apart in patients with active but stable plaque psoriasis. Part 2 of the study is a dou...
What is the current status of trial NCT00820950?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2007-05-31. Estimated completion is 2009-04-30.
What interventions are being tested in trial NCT00820950?
The interventions under investigation include: Placebo cream (DRUG), Ruxolitinib phosphate cream (DRUG), Dovonex® calcipotriene 0.005% (DRUG), Diprolene® AF betamethasone dipropionate 0.05% cream. (DRUG).
Who is sponsoring clinical trial NCT00820950?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00820950's enrollment target sits among peer trials
29 1669th of 2000 higher than 324 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI